Literature DB >> 20975740

Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H.

Bei Yang1, Chen Zhong, Yingjie Peng, Zheng Lai, Jianping Ding.   

Abstract

Human cytosolic NADP-IDH (IDH1) has recently been found to be involved in tumorigenesis. Notably, the tumor-derived IDH1 mutations identified so far mainly occur at Arg132, and mutation R132H is the most prevalent one. This mutation impairs the oxidative IDH activity of the enzyme, but renders a new reduction function of converting α-ketoglutarate (αKG) to 2-hydroxyglutarate. Here, we report the structures of the R132H mutant IDH1 with and without isocitrate (ICT) bound. The structural data together with mutagenesis and biochemical data reveal a previously undefined initial ICT-binding state and demonstrate that IDH activity requires a conformational change to a closed pre-transition state. Arg132 plays multiple functional roles in the catalytic reaction; in particular, the R132H mutation hinders the conformational changes from the initial ICT-binding state to the pre-transition state, leading to the impairment of the IDH activity. Our results describe for the first time that there is an intermediate conformation that corresponds to an initial ICT-binding state and that the R132H mutation can trap the enzyme in this conformation, therefore shedding light on the molecular mechanism of the "off switch" of the potentially tumor-suppressive IDH activity. Furthermore, we proved the necessity of Tyr139 for the gained αKG reduction activity and propose that Tyr139 may play a vital role by compensating the increased negative charge on the C2 atom of αKG during the transfer of a hydride anion from NADPH to αKG, which provides new insights into the mechanism of the "on switch" of the hypothetically oncogenic reduction activity of IDH1 by this mutation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20975740     DOI: 10.1038/cr.2010.145

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  49 in total

Review 1.  Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.

Authors:  Changcun Guo; Christopher J Pirozzi; Giselle Y Lopez; Hai Yan
Journal:  Curr Opin Neurol       Date:  2011-12       Impact factor: 5.710

2.  Novel Insights for Inhibiting Mutant Heterodimer IDH1wt-R132H in Cancer: An In-Silico Approach.

Authors:  Ezequiel Iván Juritz; Juan Pablo Bascur; Daniel Eduardo Almonacid; Fernando Danilo González-Nilo
Journal:  Mol Diagn Ther       Date:  2018-06       Impact factor: 4.074

3.  New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.

Authors:  Ujunwa C Okoye-Okafor; Boris Bartholdy; Jessy Cartier; Enoch N Gao; Beth Pietrak; Alan R Rendina; Cynthia Rominger; Chad Quinn; Angela Smallwood; Kenneth J Wiggall; Alexander J Reif; Stanley J Schmidt; Hongwei Qi; Huizhen Zhao; Gerard Joberty; Maria Faelth-Savitski; Marcus Bantscheff; Gerard Drewes; Chaya Duraiswami; Pat Brady; Arthur Groy; Swathi-Rao Narayanagari; Iléana Antony-Debre; Kelly Mitchell; Heng Rui Wang; Yun-Ruei Kao; Maximilian Christopeit; Luis Carvajal; Laura Barreyro; Elisabeth Paietta; Hideki Makishima; Britta Will; Nestor Concha; Nicholas D Adams; Benjamin Schwartz; Michael T McCabe; Jaroslav Maciejewski; Amit Verma; Ulrich Steidl
Journal:  Nat Chem Biol       Date:  2015-10-05       Impact factor: 15.040

4.  Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.

Authors:  Diego Avellaneda Matteo; Adam J Grunseth; Eric R Gonzalez; Stacy L Anselmo; Madison A Kennedy; Precious Moman; David A Scott; An Hoang; Christal D Sohl
Journal:  J Biol Chem       Date:  2017-03-22       Impact factor: 5.157

5.  Breaking Cryo-EM Resolution Barriers to Facilitate Drug Discovery.

Authors:  Alan Merk; Alberto Bartesaghi; Soojay Banerjee; Veronica Falconieri; Prashant Rao; Mindy I Davis; Rajan Pragani; Matthew B Boxer; Lesley A Earl; Jacqueline L S Milne; Sriram Subramaniam
Journal:  Cell       Date:  2016-05-26       Impact factor: 41.582

6.  Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1.

Authors:  Jason M Law; Sebastian C Stark; Ke Liu; Norah E Liang; Mahmud M Hussain; Matthias Leiendecker; Daisuke Ito; Oscar Verho; Andrew M Stern; Stephen E Johnston; Yan-Ling Zhang; Gavin P Dunn; Alykhan F Shamji; Stuart L Schreiber
Journal:  ACS Med Chem Lett       Date:  2016-08-18       Impact factor: 4.345

7.  Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase.

Authors:  Baisong Zheng; Yuan Yao; Zhen Liu; Lisheng Deng; Justin L Anglin; Hong Jiang; B V Venkataram Prasad; Yongcheng Song
Journal:  ACS Med Chem Lett       Date:  2013-06-13       Impact factor: 4.345

8.  Induced fit and the catalytic mechanism of isocitrate dehydrogenase.

Authors:  Susana Gonçalves; Stephen P Miller; Maria A Carrondo; Anthony M Dean; Pedro M Matias
Journal:  Biochemistry       Date:  2012-08-27       Impact factor: 3.162

9.  Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.

Authors:  Fangrui Wu; Hong Jiang; Baisong Zheng; Mari Kogiso; Yuan Yao; Chao Zhou; Xiao-Nan Li; Yongcheng Song
Journal:  J Med Chem       Date:  2015-08-26       Impact factor: 7.446

10.  Structural, kinetic and chemical mechanism of isocitrate dehydrogenase-1 from Mycobacterium tuberculosis.

Authors:  Christine E Quartararo; Saugata Hazra; Timin Hadi; John S Blanchard
Journal:  Biochemistry       Date:  2013-02-27       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.